March 2-3, 2023
Omni Shoreham Hotel, Washington, DC

Why is the success of immunotherapies and other targeted therapies such as gene therapy so variable within different patient populations? How can we improve these targeted therapies for widespread use in patients with hematologic diseases? Help answer these questions and more at the ASH Summit on Immunotherapies for Hematologic Diseases.

This in-person Summit is a unique meeting of the minds, bringing together  academic, medical, industry, and federal regulatory communities to address the obstacles in immunotherapy treatment development for classical and malignant hematologic conditions. Whether you’re an established academic investigator, trainee, practicing clinician, industry researcher, or federal regulator, you won’t want to miss this unique opportunity to share ideas! Through participation in this meeting, attendees will be able to:?

• Discuss fundamental advances in basic immunology that provide the foundation for immune therapies and their application
• Gain insights into critical limitations of immunotherapies and gene therapy including associated adverse events
• Examine cellular and molecular mechanisms involved in resistance and relapse associated with these therapies
• Review new immunotherapy targets
• Discuss the application of CRISPR gene editing in the development of targeted therapies
• Analyze cell manufacturing considerations
• Learn about the application of immunotherapies for the treatment of both classical hematologic and malignant diseases

TARGET AUDIENCE

The ASH Summit on Immunotherapies for Hematologic Diseases is designed to provide a wide set of learning and networking opportunities for experts in hematology, including:

• Laboratory-based scientists
• Translational and clinical researchers
• Practitioners interested in the application of immunotherapies
• Young investigators (trainees)
• Cellular therapy, gene therapy, biopharmaceutical, and life sciences industry experts
• Regulatory scientists

REGISTER

Call for Summit Abstracts

For the first time in this meeting series, the Society is accepting abstracts to be presented at the Summit. Annual meeting abstract submitters and presenters are encouraged to submit their abstracts for consideration!

Abstract submission site opens	November 15, 2022
Abstract submission deadline	January 5, 2023, at 11:59 p.m. Pacific time
Late-breaking abstract submission site opens	January 24, 2023
Late-breaking abstract submission deadline	January 31, 2023, at 11:59 p.m. Pacific time

VIEW ABSTRACT CATEGORIES

SUBMIT AN ABSTRACT

View the Schedule at-a-Glance for additional details on the Summit’s program.

Hotel Information

ASH has secured discounted hotel rooms at the Omni Shoreham Washington, DC

LEARN MORE

2023 Program Co-Chairs

• Shannon Maude, MD, PhD,?Children’s Hospital of Philadelphia
• Terry Fry, MD,?University of Colorado School of Medicine and Sana Biotechnology
• Neal Young, MD,?National Institutes of Health

ASH Summit Steering Committee

• Catherine Bollard, MD, Children’s National Medical Center?
• Rodrigo Calado, MD, PhD, University of Sao Paulo?
• Sarah Cooley, MD, MS, Fate Therapeutics?
• Madhav Dhodapkar, MD, Emory University?
• Stephen Forman, MD, City of Hope?
• Frederick Locke, MD, Moffitt Cancer Center?
• Loretta?Nastoupil, MD, MD Anderson Cancer Center?
• Jae Park, MD, Memorial Sloan Kettering Cancer Center?
• Katy?Rezvani, MD, PhD, Anderson Cancer Center?
• Antonio Risitano,?MD, PhD,?University of Naples?
• David Scott,?MS, PhD,?Uniformed Services University of Health Sciences?
• Guy Young,?MD,?Children’s Hospital of Los Angeles?

Questions?

For questions about the program for the 2023 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Deputy Director of Scientific Affairs Alice Kuaban at?akuaban@hematology.org.

For general inquiries about this meeting, please submit them to?ashsummit@hematology.org.